(Total Views: 538)
Posted On: 09/03/2020 1:02:20 AM
Post# of 37
$RVVTF PAY ATTENTION TO CATALYSTS I POST BELOW: by powerbattles
Hospital selection USA trials.
IND FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19
FDA Authorized emergency IND (eIND
UPGRADE OCQB
Grant/Funding opportunities
Sponsor for Trials
Initiate Phase 3 clinical trials of Bucillamine in the treatment of COVID-19 in the U.S
Expand Phase 3 Clinical Trials COVID-19 in Asia-Pacific and Canada
Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
Update the final Prototype orally dissolvable thin film strip for psilocybin
Patents-pending psilocybin formulations
Finalize vendor agreements in project management, medical monitoring, and data management.
Patent News Updates:
[Suppressed Image]
Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
Q3/4 Results from Phase 2 clinical study of Bucillamine in the treatment of COVID-19
Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
Potential buyout could be Billions for a biotech company
Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT This could lead to potential partnership/deals in the future. IMHO
)
Update on its Psilocybin-Based Pharmaceutical Program
Partners to Advance Research for Psilocybin-Based Pharmaceutical Products
Update drugs research partnership agreement (“SRPA”) with the University of Wisconsin-Madison
Link to Revive's subsidiary company
https://www.psilocinpharma.com/
Revive Therapeutics, MindMed, Compass Pathways & Delic Corp Embark on Psychedelics MDMA, Ayahuasca, Psiloc https://financial-news-now.com/revive-therape...-ketamine/
Revive Therapeutics First to Bring Oral Psilocybin Strips to the Market
https://www.greenmarketreport.com/revive-ther...he-market/
Market Size Potential for Psychedelic Medicine
over $200 billion was spent directly on mental health issues in the United States last year. worldwide market equates to $607 billion in direct costs outside of the US, with indirect costs still being multiples of that.
https://mushroomstockindex.com/article/market...-medicine/
Hospital selection USA trials.
IND FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19
FDA Authorized emergency IND (eIND
UPGRADE OCQB
Grant/Funding opportunities
Sponsor for Trials
Initiate Phase 3 clinical trials of Bucillamine in the treatment of COVID-19 in the U.S
Expand Phase 3 Clinical Trials COVID-19 in Asia-Pacific and Canada
Q2 Submit IND for Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q2/3 Pre-IND meeting with FDA for Bucillamine in various infectious diseases (undisclosed)
Update the final Prototype orally dissolvable thin film strip for psilocybin
Patents-pending psilocybin formulations
Finalize vendor agreements in project management, medical monitoring, and data management.
Patent News Updates:
[Suppressed Image]
Q3 Initiate Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q3 Pre-IND meeting with FDA for Psilocybin (undisclosed indications)
Q3/4 Results from Phase 2 clinical study of Bucillamine in the treatment of COVID-19
Q4 Results from Phase 2 clinical study of CBD in the treatment of Autoimmune Hepatitis
Q4 Submit FDA IND for Phase 2 clinical study of Bucillamine (undisclosed indication)
Potential buyout could be Billions for a biotech company
Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT This could lead to potential partnership/deals in the future. IMHO
) Update on its Psilocybin-Based Pharmaceutical Program
Partners to Advance Research for Psilocybin-Based Pharmaceutical Products
Update drugs research partnership agreement (“SRPA”) with the University of Wisconsin-Madison
Link to Revive's subsidiary company
https://www.psilocinpharma.com/
Revive Therapeutics, MindMed, Compass Pathways & Delic Corp Embark on Psychedelics MDMA, Ayahuasca, Psiloc https://financial-news-now.com/revive-therape...-ketamine/
Revive Therapeutics First to Bring Oral Psilocybin Strips to the Market
https://www.greenmarketreport.com/revive-ther...he-market/
Market Size Potential for Psychedelic Medicine
over $200 billion was spent directly on mental health issues in the United States last year. worldwide market equates to $607 billion in direct costs outside of the US, with indirect costs still being multiples of that.
https://mushroomstockindex.com/article/market...-medicine/
(0)
(0)
$MJ
